Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash & Equivalents (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Cash & Equivalents for 14 consecutive years, with $30.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 47.2% to $30.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.0 million through Dec 2025, up 47.2% year-over-year, with the annual reading at $31.0 million for FY2025, 54.71% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $30.0 million at Aytu Biopharma, down from $32.6 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $49.9 million in Q2 2021, with the low at $18.2 million in Q1 2025.
  • Average Cash & Equivalents over 5 years is $25.8 million, with a median of $20.4 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents plummeted 61.2% in 2022, then surged 62.27% in 2025.
  • Over 5 years, Cash & Equivalents stood at $35.3 million in 2021, then crashed by 44.72% to $19.5 million in 2022, then grew by 0.14% to $19.5 million in 2023, then grew by 4.45% to $20.4 million in 2024, then surged by 47.2% to $30.0 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $30.0 million, $32.6 million, and $31.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.